ST. JOSEPH, MO -- Boehringer Ingelheim Vetmedica, Inc. introduces a vaccine that steps beyond conventional reproductive protection. Express® FP 5-VL5 currently provides one of the most complete modified-live virus/bacterin vaccine combinations on the market, and now it offers protection against Leptospira hardjo-bovis.

Leptospira hardjo-bovis is associated with early embryonic deaths, poor conception rates, weak calves as well as other reproductive losses in cattle. Express FP 5-VL5 offers five-way viral protection and protection against Lepto hardjo-bovis in just one syringe. Lepto hardjo-bovis (Leptospira borgpetersenii serovar hardjo type hardjo-bovis) is the only hardjo that is isolated in the United States; all cattle herds are at risk for infection from it. In a recent study, challenged heifers vaccinated with Express FP 5-VL5 were 100 percent protected against urinary shedding of Lepto hardjo-bovis, while urine culture tests for all heifers in the control group were positive.1

“As demonstrated by new label claims and the guarantee Boehringer Ingelheim Vetmedica puts behind this product, the introduction of Express FP 5-VL5 offers the cattle industry an effective vaccine for reproductive and respiratory protection in the cowherd,” says Dr. Joe Campbell, Boehringer Ingelheim Vetmedica, Inc. professional services veterinarian.

This new product also includes antigens for bovine respiratory syncytial virus (BRSV) and parainfluenza-3 (PI3), as well as new label claims for prevention of urinary shedding of Lepto hardjo-bovis and aids in the prevention of key respiratory viruses. The expanded respiratory label adds to the reproductive protection in beef and dairy cattle that Express FP products have long been known for.

The Express FP line of vaccines for breeding animals offers producers the original written guarantee that no calf persistently infected with BVD will be born from a properly vaccinated cow. It is reproductive and respiratory protection that producers can count on every time.

“Express FP was the first modified-live viral vaccine to offer a written guarantee that calves born to a dam properly vaccinated with Express FP would be free of BVD persistent infection,” Campbell says. “This vaccine was created with your herd’s reproductive health in mind, protecting your animals against major reproductive diseases. The efficacy of Express FP has always been our top priority, and we will continue to offer that guarantee on our product.”

Read and follow all product label directions. For more information on Express FP, contact your veterinarian or Boehringer Ingelheim Vetmedica, Inc. representative.

Boehringer Ingelheim Vetmedica, Inc. (St. Joseph, Mo.) is a subsidiary of Boehringer Ingelheim Corporation, based in Ridgefield, Conn., and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and approximately 41,500 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2009, Boehringer Ingelheim posted net sales of US $17.7 billion (12.7 billion euro) while spending 21 percent of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information, please visit:

1Protection for Lepto borgpetersenii serovar hardjo using Express FP. BIVI TB10-138.